The market reaction to Friday’s update from Sanofi and partner Regeneron on experimental respiratory drug itepekimab looks overdone, according to Berenberg. Moreover, Sanofi’s pipeline renaissance is ...

[Click here for information about joining the class action] On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Just five weeks later, Sanofi has made a deal few would describe as “bolt-on,” as it has bought out Blueprint Medicines for $9.5 billion. Sanofi buys Blueprint for $9.5B, its largest deal in 7 ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY ... Anti-drug antibodies were rare and had no apparent impact on itepekimab drug levels. Sanofi and Regeneron are ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.

Sanofi (ENXTPA:SAN) announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the ...

Sanofi (ENXTPA:SAN) announced that its AERIFY-1 trial with Regeneron Pharmaceuticals successfully met its primary endpoint, indicating progress in COPD treatment. Despite this positive news, the ...